ArticleJournal of cataract and refractive surgery2026
Real-world characteristics and safety outcomes of 10 000 eyes treated with intracanalicular dexamethasone insert: IRIS registry analysis 2019 to 2021.
Article in Journal of cataract and refractive surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo characterize real-world patient profiles and safety-related diagnoses from the first 10 000 eyes receiving the dexamethasone intracanalicular (DEX) insert indicated for the treatment of ocular inflammation and pain after ophthalmic surgery.
settingAmerican Academy of Ophthalmology Intelligent Research in Sight Registry.
designRetrospective cohort study of electronic health records.
methodsAll eyes that received DEX 2 days before or up to 7 days after cataract surgery (DEX+ group) between June 1, 2019 (start of commercialization), and March 31, 2021, were identified by procedure coding. A control cohort of eyes not receiving DEX (DEX- group) was drawn from the same practices as DEX+ eyes. Outcomes included characterization of demographics, comorbidities, and safety events of interest.
results10 313 DEX+ and 425 098 DEX- eyes were analyzed of 3 703 177 eyes undergoing cataract procedures during the index period. Eyes with a history of coded conditions relating to ocular surface disease (OSD) received DEX at a higher rate than eyes without a history of OSD (n = 3311 [32.1%] vs n = 104 205 [24.5%], P < .0001), and approximately one-quarter of eyes in both cohorts had preexisting glaucoma (n = 2634 and n = 105 700 eyes, respectively). Postoperative inflammatory events, corneal edema, and lacrimal disorders were uncommon (<2%) and had a comparable incidence in both cohorts. In DEX+ and DEX- eyes, the incidence of cystoid macular edema (n = 130, 1.3% and n = 2673, 0.6%, respectively, P < .0001) and epiphora (n = 73, 0.7% and n = 899, 0.2%, respectively, P < .0001) was low. DEX+ and DEX- cohorts had comparable incidence of intraocular pressure (IOP) elevations ≥10 mm Hg and similar mean IOP changes through postoperative month 1.
conclusionsThe DEX insert was found to have comparable inflammation, lacrimal disorder, and IOP outcomes with alternate perioperative therapy after cataract surgery, and real-world safety outcomes in this cohort of more than 10 000 eyes were similar to those observed in prior DEX clinical trials. The DEX intracanalicular insert may be considered as a suitable alternative treatment option to topical anti-inflammatory drops in patients undergoing cataract surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.